Avidity Biosciences, Inc. (RNA)
Automate Your Wheel Strategy on RNA
With Tiblio's Option Bot, you can configure your own wheel strategy including RNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RNA
- Rev/Share 0.0828
- Book/Share 9.2011
- PB 7.5904
- Debt/Equity 0.0043
- CurrentRatio 9.2592
- ROIC -0.4215
- MktCap 8985512434.0
- FreeCF/Share -3.8782
- PFCF -17.8746
- PE -19.8638
- Debt/Assets 0.0038
- DivYield 0
- ROE -0.3345
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RNA | Roth Capital | -- | Buy | -- | $62 | Sept. 17, 2025 |
| Resumed | RNA | Goldman | -- | Buy | -- | $55 | July 10, 2025 |
| Initiation | RNA | Bernstein | -- | Outperform | -- | $50 | June 24, 2025 |
| Initiation | RNA | Wolfe Research | -- | Outperform | -- | $55 | June 17, 2025 |
| Initiation | RNA | Raymond James | -- | Strong Buy | -- | $65 | June 11, 2025 |
| Initiation | RNA | Citigroup | -- | Buy | -- | $70 | March 13, 2025 |
| Initiation | RNA | BMO Capital Markets | -- | Outperform | -- | $72 | March 12, 2025 |
| Initiation | RNA | Scotiabank | -- | Sector Outperform | -- | $70 | March 7, 2025 |
| Initiation | RNA | H.C. Wainwright | -- | Buy | -- | $72 | Dec. 20, 2024 |
| Initiation | RNA | Goldman | -- | Buy | -- | $59 | Sept. 24, 2024 |
News
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Read More
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Read More
Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Avidity Biosciences (RNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday
Published: October 27, 2025 by: Investopedia
Sentiment: Positive
Shares of Avidity Biosciences (RNA) soared more than 40% Monday after Novartis (NVS) agreed to buy the U.S. biopharmaceutical firm for about $12 billion in cash to expand its RNA-based disease-fighting pipeline.
Read More
Is it too late to buy Avidity stock after Novartis deal?
Published: October 27, 2025 by: Invezz
Sentiment: Positive
Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announcement sent RNA shares soaring roughly 44% in a single session – indicating investor enthusiasm and confidence in the buyout terms.
Read More
RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Read More
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
Published: October 26, 2025 by: WSJ
Sentiment: Positive
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Read More
Novartis to acquire Avidity Biosciences for about $12B
Published: October 26, 2025 by: New York Post
Sentiment: Neutral
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.
Read More
Novartis Deal Values Avidity Biosciences At $12 Billion
Published: October 26, 2025 by: Barrons
Sentiment: Positive
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Read More
Novartis to acquire Avidity Biosciences for $12 billion
Published: October 26, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Read More
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Published: October 26, 2025 by: PRNewsWire
Sentiment: Neutral
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a new company ("SpinCo") Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions SAN DIEGO , Oct. 26, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it has entered into a definitive merger agreement …
Read More
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipeline Expected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, and bolsters mid-single digit long-term growth As part of the agreement, Avidity will separate its early-stage precision cardiology programs into a new company (“SpinCo”) prior to closing Consideration totals USD 12bn in cash; closing expected in …
Read More
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Published: October 26, 2025 by: CNBC
Sentiment: Positive
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Read More
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the Company completed a positive pre-BLA meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming BLA submission of delpacibart zotadirsen (del-zota). Del-zota, which received Breakthrough Therapy designation, is an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy who have gene mutations amenable to exon 44 skipping (DMD44).
Read More
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Published: October 06, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that it will deliver late-breaking oral and poster presentations at the 30th Annual International Congress of the World Muscle Society (WMS), to be held October 7-11, 2025, in Vienna, Austria. The data to be presented at WMS will reinforce and build on the positive data announced by Avidity in September 2025 which showed reversal of disease progression and unprecedented improvement compared to baseline …
Read More
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
Published: September 11, 2025 by: Seeking Alpha
Sentiment: Positive
Avidity Biosciences remains a Strong Buy for me, driven by Del-zota's promising data in targeting Duchenne Muscular Dystrophy exon 44 skipping patients. Del-zota showed sustained 25% dystrophin production and 80% CK reduction over 16 months, with functional improvements versus natural history. A BLA filing for Del-zota under Accelerated Approval is expected by year-end 2025, with additional data and catalysts ahead in 2025-2026.
Read More
Avidity Biosciences to Participate in Upcoming Investor Conferences
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conferences: Cantor Global Healthcare Conference 2025 – New York, NY Wednesday, September 3, 2025, at 7:20 a.m. PT | 10:20 a.m.
Read More
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
Read More
Novartis weighs deal for biotech Avidity Biosciences, FT reports
Published: August 06, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
Read More
Avidity Biosciences to Participate in Upcoming Investor Conference
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m.
Read More
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Published: April 08, 2025 by: PRNewsWire
Sentiment: Neutral
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the …
Read More
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Published: March 31, 2025 by: PRNewsWire
Sentiment: Neutral
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO , March 31, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the biomarker cohort in the Phase 1/2 …
Read More
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. "Rare Disease Day represents an important opportunity for all of us, including people living with rare diseases, their friends, family and caregivers, and advocacy organizations …
Read More
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.
Read More
Avidity Biosciences to Participate in Upcoming Investor Conferences
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00 p.m.
Read More
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,000 shares of its common stock and 53,500 restricted stock units ("RSUs") to twenty-two (22) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees …
Read More
About Avidity Biosciences, Inc. (RNA)
- IPO Date 2020-06-12
- Website https://www.aviditybiosciences.com
- Industry Biotechnology
- CEO Sarah Boyce
- Employees 391